| Literature DB >> 35392567 |
Kelly M Martinovich1,2,3, Anthony Kicic1,2,4,5,6, Stephen M Stick1,2,4,5, Russell D Johnsen3,7, Sue Fletcher3,7,8, Steve D Wilton3,7.
Abstract
Introduction: Severity and disease progression in people with Cystic Fibrosis (CF) is typically dependent on their genotype. One potential therapeutic strategy for people with specific mutations is exon skipping with antisense oligonucleotides (AO). CFTR exon 9 is an in-frame exon and hence the exclusion of this exon would excise only 31 amino acids but not alter the reading frame of the remaining mRNA. Splice mutations 1209 + 1 G > C and 1209 + 2 T > G were documented to cause CFTR exon 9 skipping and these variants were reported to manifest as a milder CF disease, therefore exon 9 skipping could be beneficial for people with class I mutations that affect exon 9 such as p.Trp401X. While the impact of exon 9 skipping on gene expression and cellular pathways can be studied in cells in vitro, trace amount of full-length normal or mutated material could confound the evaluation. To overcome this limitation, the impact of CFTR exon 9 skipping on disease phenotype and severity is more effectively evaluated in a small animal model. It was hypothesised that antisense oligonucleotide-mediated skipping this particular exon could result in a "mild mouse CF phenotype".Entities:
Keywords: cystic fibrosis transmembrane conductance regulator; exon deletion; exon skipping therapy; mouse model; transgenic mouse
Year: 2022 PMID: 35392567 PMCID: PMC8981082 DOI: 10.3389/fphar.2022.868863
Source DB: PubMed Journal: Front Pharmacol ISSN: 1663-9812 Impact factor: 5.810
FIGURE 1Survival plot of Cftr mice. At time of weaning (21 days) Cftr mice had a survival of 83% which dropped to 38% by day 50, with most mice succumbing to intestinal obstruction or malnutrition (solid line). Heterozygous mice did not show decreased survival with 89% survival at day 50 until day 150 when monitoring ended (dashed line). n = 24.
FIGURE 2Hematoxylin and Eosin and Alcian Blue staining of representative lung and intestinal sections from Cftr and Cftr (control) mice. (A–F) Hematoxylin and Eosin stained (A). Lung section for Cftr mouse. (B). Lung section for Cftr mouse. (C). Small intestinal section from Cftr mouse. (D). Intestinal section from Cftr mouse. (E). Crypts of Lieberkühn section from Cftr mouse. (F). Lieberkühn section from Cftr mouse. (G–J) Alcain blue stained (G). a Cftr mouse and (H). Cftr mouse showing Crypts of Lieberkühn. Sections of small intestine from (I). Cftr mouse and (J). Cftr mouse, showing goblet cells. n = 4. Images (A,B), (E–H) were taken at ×40 (scale bar 20 micrometres) and (C,D), (I,J) were taken at ×20 (scale bar 50 micrometres).
FIGURE 3CftrΔ9/Δ9 deleted airway epithelial cell morphology. (A). Airway epithelial cells grown in monolayer had standard cobble stone appearance. Scale bar: 30 micrometres (B). Airway epithelial cells grown at the air-liquid interface with the dense packed growth morphology. Scale bar 30 micrometres. n = 4.
FIGURE 4Cftr epithelial cell CFTR function. (A,B). Ussing chamber tracing showing change in short circuit current (Isc) in response to drug stimulation on Cftr ALI cultures pre-treated for 24 h with DMSO. (C,D). Ussing chamber tracing showing change in Isc in response to drug stimulation on homozygote Cftr exon 9 deleted ALI cultures pre-treated for 24 h with Lumacaftor. (E). Summary of changes in Isc in response to amiloride, forskolin and CFTR inhibitor-172 for Cftr ALI cultures pre-treated with DMSO (Black bars) or Lumacaftor (Grey bars) (Isc, n = 2). Pre-treatment with DMSO (black bar) pre-treatment with Lumacaftor (blue bar), Amiloride addition (green bar), Forskolin stimulation (yellow bar), Ivacaftor stimulation (orange bar), CFTR inhibitor-172 (CI-red bar).